Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

December 21, 2020 8:30 AM

Company Regains Compliance with NASDAQ Minimum Bid Requirement IRVINE, CA / ACCESSWIRE / December 21, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Company has received formal notification from the NASDAQ Hearings Panel (the "Panel") that the Company has evidenced full compliance with the minimum bid price...

Read more

Tetra Bio-Pharma Confirms it is on Track to Receive Government Funding

December 21, 2020 6:30 AM

Tetra Provides Update on ARDS-003 Tetra Eyes Global Sepsis Market OTTAWA, ON / ACCESSWIRE / December 21, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced that it expects government funding to help accelerate its sepsis and acute respiratory distress syndrome (ARDS) drug development. As the first...

Read more

Havn Life Sciences Files Preliminary Prospectus in Connection with Bought Deal Equity Financing

December 18, 2020 6:55 PM

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / December 18, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life") is pleased to announce, further to its previously announced offering (the "Offering") on December 15, 2020, that it has filed a preliminary short form prospectus (the "Preliminary Prospectus")...

Read more

Else Nutrition Clarifies News Release Regarding Deemed Insider Share Disposition

December 18, 2020 5:30 PM

VANCOUVER, BC / ACCESSWIRE / December 18, 2020 / Else Nutrition Holdings (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) ("Else" or the "Company") wishes to clarify the purpose of the December 15 news release issued on behalf of Ms. Hamutal Yitzhak, the CEO of the Company, announcing the filing of an Early Warning Report required under Canadian laws. Ms. Yitzak did not sell or otherwise dispose of any of the shares referenced in that...

Read more

JOYN Botanicals Signs Joint Venture Agreement with Cannabis Processor Adastra Labs, to Manufacture and Bring Solucann Powder to Cannabis 3.0 Market

December 18, 2020 10:00 AM

TORONTO, ON / ACCESSWIRE / December 18, 2020 / JOYN Botanicals Ltd. ("JOYN") is pleased to announce it has signed a joint venture ("JV") agreement with Adastra Labs Holdings Ltd. (XTRX) (D2EP) ("Adastra") a Health Canada Licensed cannabis processing and analytical testing services Company, for the exclusive Canadian use of its patent-pending Solucann water soluble cannabis powder for addition into Cannabis 3.0...

Read more

Wuhan General Group Expands into UK Market with Medspresso

December 18, 2020 9:30 AM

CAPE TOWN, SA / ACCESSWIRE / December 18, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update: The Company is set to expand into the European market with its recently launched Medspresso™ line of CBD infused hot beverages. Medspresso™ is...

Read more

Adastra Signs Joint Venture Agreement with JOYN Botanicals to Solidify Cannabis 3.0 Edible and Beverage Technology Partnership

December 18, 2020 7:00 AM

LANGLEY, BC / ACCESSWIRE / December 18, 2020 / Adastra Labs Holdings Ltd. (CSE:XTRX)(FRANKFURT:D2EP) ("Adastra") a Health Canada Licensed cannabis processing and analytical testing services Company, is pleased to announce it has signed a joint venture ("JV") agreement with JOYN Botanicals Ltd. ("JOYN") for the exploitation of JOYN's patent-pending soluble cannabis powder. Joint Venture Terms Under the...

Read more

MJ BIOTECH, INC., Forms a Wholly-Owned Subsidiary, New England Biotech, Inc., Entering the HEMP/AGRICULTURE / EXTRACTION sectors - COVID-19 Test kits Update

December 17, 2020 8:30 AM

CHEYENNE, WY / ACCESSWIRE / December 17, 2020 / MJ BIOTECH INC. (OTCQB:MJTV), today announced that it has incorporated a new company - New England Biotech, Inc., in the State of Maine, to enter the robust HEMP/AGRICULTURE / EXTRACTION business. MJTV management felt it would be a dereliction of responsibility to not enter the explosive opportunity presented by the Covid-19 test kit business due to the relationships it has in this sector. Great...

Read more

Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy

December 17, 2020 1:00 AM

First-in-human data from ongoing phase 1 study of MP0310 (AMG 506) demonstrate encouraging biological activity, including successful localized tumor engagement and saturation Data from ongoing phase 1 COVID-19 study show that MP0420 (ensovibep) is well tolerated in first dose cohort Unique immunomodulation platforms advanced to readiness for candidate generation using CD-3 T cell engagers and pMHC binders Virology...

Read more

MobiWellness Is Now America's Largest Mobile Hormone Replacement Therapy Service

December 16, 2020 11:00 AM

MobiWellness now offers hormone therapy for men and women, right in your home or office, in 20 cities and growing WILMINGTON, DE / ACCESSWIRE / December 16, 2020 / MobiWellness, Inc. is an online platform that helps connect patients with doctors that are hormone therapy experts in the patient's state. What is even more valuable, is that thanks to the MobiWellness platform, there is no longer a need to go visit any clinics or labs again,...

Read more

DECN Provides Testing Update for US, Korea and XPRIZE With Plans for Walk-in Donor Study for at-Home GenViro! Saliva Swift :10 Test Kit

December 16, 2020 9:15 AM

As clinical testing in Pennsylvania nears completion for pro and point of care GenViro! kits, Korean partner initiates PCR validation testing to augment testing of their saliva donors and the XPRIZE samples DECN plans 150 patient donor study to complete its at-home testing kit EUA LOS ANGELES, CA / ACCESSWIRE / December 16, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co, a leading manufacturer and worldwide...

Read more

Hancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day Milestone

December 16, 2020 8:30 AM

Electrocardiograms Indicate Good Cardiac Function for Both Patients IRVINE, CA / ACCESSWIRE / December 16, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that two patients who have undergone heart bypass surgeries utilizing HJLI's CoreoGraft have reached the 30-day milestone and are reported to have good cardiac function. The first two...

Read more

Havn Life Sciences Hits Major Milestone with Research Partner, Complex Biotech Discovery Ventures

December 16, 2020 8:00 AM

Havn Research signs contract with CBDV, located at The University of British Columbia's Vancouver campus, to begin Health Canada approved research to analyze psilocybin under Havn Life's Section 56 exemption. The results of the analysis will allow Havn Life to begin the development of a library of psilocybin compounds. VANCOUVER, BC / ACCESSWIRE / December 16, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the...

Read more

Tetra Bio-Pharma Hits Another Milestone Before Year End

December 16, 2020 6:30 AM

Tetra will accelerate its Inhaled synthetic THC drug approvals under a 505(b)(2) marketing application pathway FDA confirms clinical development program to support marketing application of Tetra's inhaled innovative THC drug OTTAWA, ON / ACCESSWIRE / December 16, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today...

Read more

Helix Biopharma Corp. Announces Fiscal 2021 First Quarter Results

December 15, 2020 11:50 PM

RICHMOND HILL, ON / ACCESSWIRE / December 15, 2020 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced its fiscal 2021 first quarter results for the period ending October 31, 2020. OVERVIEW The Company reported a net loss and total...

Read more

Ron Kilgarlin on How American Screening LLC Facilitates Efficient Decision-Making with Vast Selection of Rapid Drug Tests

December 15, 2020 5:40 PM

SHREVEPORT, LA / ACCESSWIRE / December 15, 2020 / Certain issues remain a common worldwide challenge despite the social progress and economic prosperity achieved in the past few decades. One of them is illicit drug use, which has been straining healthcare budgets, affecting workplace productivity, and endangering public safety. However, medical and technological advances have enabled government agencies, healthcare professionals, employers, and...

Read more

Hancock Jaffe Announces Significant Improvements in all Study Endpoints For Final VenoValve First-in-Human Data

December 15, 2020 4:15 PM

Patients Show Significant Improvements in Reflux, VCSS, and VAS Scores IRVINE, CA / ACCESSWIRE / December 15, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the final aggregated data for the VenoValve first-in-human trial shows significant improvements in all study endpoints. For the eleven patients in the first-in-human study,...

Read more

Apollo Endosurgery Receives FDA Clearance for the X-Tack(TM) Endoscopic HeliX Tacking System

December 15, 2020 4:00 PM

AUSTIN, TX / ACCESSWIRE / December 15, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today U.S. Food and Drug Administration 510k clearance of the X-Tack™ Endoscopic HeliX Tacking System. X-Tack is a new, through-the-scope, suture-based device designed specifically for closing and healing defects in the lower...

Read more

Viewpoint Molecular Targeting(TM) Closes $8 Million in First Tranche of Series A Financing

December 15, 2020 11:00 AM

Company focused on developing precision α-particle radiopharmaceutical oncology drugs and complementary diagnostic imaging agents that have the potential to optimize patient care Funds from Series A expected to propel two lead radiopharmaceutical programs, VMT01 and VMT-𝛼-NET into Phase 1 imaging studies beginning before year-end 2020 and accelerate development of radioisotope production technologies CORALVILLE, IA / ACCESSWIRE...

Read more

DPS and TRIA Complete First Phase for Arranta Bio's Manufacturing Facility

December 15, 2020 9:10 AM

BOSTON, MA / ACCESSWIRE / December 15, 2020 / DPS Group, a privately-owned, global engineering, procurement, construction management, and validation (EPCMV) firm serving high-tech process industries, and TRIA, a principal-led architecture firm with a focus on designing unique spaces for science, technology, and corporate clients, are pleased to announce the completion of the first phase of the 80,000 SF Arranta Bio Manufacturing Facility....

Read more